

Table S1: Subsequent Anti-cancer Therapy Following Nivolumab in VOLUME Patients (N=447)

	N (%)
Any anti-cancer therapy	140 (31.3)
Any surgery	6 (4.3)
Any radiotherapy	47 (33.6)
Any cytotoxic drugs	104 (74.3)
Paclitaxel*	64 (61.5)
Carboplatin*	26 (25.0)
Cetuximab*	24 (23.1)
Methotrexate*	20 (19.2)
Docetaxel*	18 (17.3)
5-fluorouracil*	8 (7.7)
Cisplatin*	7 (6.7)
Other*	23 (22.1)

\* Only assessed for patients with at least one cytotoxic drug

Percentages based on the number of patients with at least one post-nivolumab treatment and non-missing data.